Regenerative Medicine Weekly Trend Line

Mar. 14, 2011 1:28 PM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Long/Short Equity, Special Situations, Contrarian

Contributor Since 2009

Editor and Publisher ... Henry enters his thirteen (13) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine - stem, gene and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis. He was VP - Strategic Planning and Communication at Curis (2001-2002), HQCM focusing on healthcare investments (NYSE:HQH/HQL) from (1985-2001)and founded LifeScience Economics, a healthcare research and analytics firm with offices in Boston, MA and Palo Alto, CA. Past experiences include Thermo Scientific, SWEC following 5 years at the FBI. A former military officer, Henry has been an adjunct professor at Boston University and Golden Gate University where he taught courses in venture capital, corporate finance and strategic development in the universities' graduate business schools.

Visibility with elements of viability continues to be the indicators of volume initiatives…

Some shares of regenerative medicine companies lost and regained lost ground by Friday, 3/11/11, after being (yet again) pushed up but, mostly down during the week.

  • At the end of the week, US stocks were up 3/11/11… having started out rocky in the beginning hours based on oil prices and Japan’s earthquake(s) and resulting Tsunami, economic worries abroad and in the US.

Advancers (7):  Cytori (CYTX) up $0.72 (10.98%) to $7.28; Athersys (ATHX) up $0.03 (1.20%) to $2.53; Aastrom (ASTM) up $0.02 (0.86%) to $2.34; International Stem Cell (OTCQB:ISCO) up $0.03 (2.34%) to $1.31;  BioTime (AMEX: BTX) up $0.34 (4.38%) to $8.11 and NeoStem (AMEX: NBS)  up $0.03 (1.87%) to $1.63 and ThermoGenesis (KOOL) up 0.05 (2.38%) to $2.15.

Decliners (12): Geron (GERN) down -$0.02 (-0.41%) to $4.83; Opexa (OPXA) down $0.01 (-0.57%) to $1.73; Pluristem (PSTI) down $0.01 (-0.42%) to $2.39; Osiris (OSIR) down $0.34 (-5.26%) to $6.12; Advanced Stem Cell Technology (OTC: ACTC) down -$0.002 (10.41%) to $0.165; StemCells (STEM) down $0.008 (-0.95%) to $0.811;  Brainstorm (BCLI) down -$0.001 (-0.32%) at $0.309;  ReNeuron Group (RENE.L) down -$0.03 (-0.44%) to $5.67; Tengion (TNGN) down -$0.13 (-4.69%) to $2.64; BioMimetic (BMTI) down -$0.07 (-0.55%) to $12.65; Neuralstem (AMEX:CUR) down -0.03 (-1.61%) to $1.83 and ImmunoCellar Therapeutics (OTCPK:IMUC) down $0.01 (-0.42%) to $2.39.

Flat (1): BioHeart (OTCPK:BHRT) at $0.21.

The Bottom Line: Cytori Therapeutics (CYTX) was the biggest winner which was up $0.72 to $7.28 or 10.98% based on good Q4/10 earnings and regulatory updates. In the spotlight, CYTX grew product sales 41% and made substantial progress in advancing its cardiovascular device product pipeline during 2010 in a universe of development spending companies. A continual up is AMEX: BTX. From the 3/11/11close, the market’s indication still is a lack of real conviction. Total short interest has grown markedly in recent years for reasons having much to do with a particular company’s stock but having little or nothing to do with the overall market. In the regenerative medicine universe, short sale data seem to carry significance. This doesn’t mean that short-sellers will be wrong about individual company viability and visibility. Declining stocks (12 to 7) outpaced those advancing, a most notable indicator. The regenerative medicine universe market indicates a lack of real conviction while the NASDAQ closed up 14.59 or 0.54% to 2715.61.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.